UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Enhanced Skin Deposition of Betamethasone Dipropionate from a Novel Formulation and Drug Delivery Technology

Dermatology and therapy, 2023-08, Vol.13 (8), p.1763-1771

2023

Volltextzugriff (PDF)

Calcipotriene and Betamethasone Dipropionate PAD-Cream Demonstrates Greater Treatment Efficacy in Patients with Moderate-to-Severe Psoriasis Compared to Topical Suspension/Gel: A Subgroup Analysis of Two Phase 3 Studies

Dermatology and therapy, 2023-09, Vol.13 (9), p.2031-2044

2023

Volltextzugriff (PDF)

Sensory properties analysis of a calcipotriol and betamethasone dipropionate cream vehicle formulated with an innovative PAD Technology for the treatment of plaque psoriasis on the skin and scalp

Drugs in Context, 2023-03, Vol.12, p.1-8

2023

Volltextzugriff (PDF)

Calcipotriol and Betamethasone Dipropionate Cream Based on PAD Technology for the Treatment of Plaque Psoriasis: A Narrative Review

Dermatology and therapy, 2023-10, Vol.13 (10), p.2153-2169

2023

Volltextzugriff (PDF)

Polyaphron Dispersion Technology, A Novel Topical Formulation and Delivery System Combining Drug Penetration, Local Tolerability and Convenience of Application

Dermatology and therapy, 2022-10, Vol.12 (10), p.2217-2231

2022

Volltextzugriff (PDF)

Profiling of multiple signal pathway activities by multiplexing antibody and GFP-based translocation assays

Combinatorial chemistry & high throughput screening, 2008-08, Vol.11 (7), p.537-544

2008

Volltextzugriff (PDF)

Validation of the Self-Reported Psoriasis Treatment Convenience Scale (PTCS)

Dermatology and therapy, 2021-12, Vol.11 (6), p.2077-2088

2021

Volltextzugriff (PDF)

Enhanced Skin Deposition of Betamethasone Dipropionate into the Skin of Human Volunteers from Calcipotriene/Betamethasone Dipropionate Cream Compared to Topical Suspension

Skin (Milwood, N.Y.), 2022-11, Vol.6 (6), p.s54

2022

Volltextzugriff (PDF)

A Phase 3, Randomized Trial Demonstrating the Improved Efficacy and Patient Acceptability of Fixed Dose Calcipotriene and Betamethasone Dipropionate Cream

Journal of drugs in dermatology, 2021-04, Vol.20 (4), p.420-425

2021

Volltextzugriff (PDF)

Topical cyclosporin A as a steroid‐sparing agent for ocular rosacea

Acta ophthalmologica (Oxford, England), 2017-03, Vol.95 (2), p.e158-e159

2017

Volltextzugriff (PDF)

An anchored matching-adjusted indirect comparison of fixed-dose combination calcipotriol and betamethasone dipropionate (Cal/BDP) cream versus Cal/BDP foam for the treatment of psoriasis

The Journal of dermatological treatment, 2022-11, Vol.33 (8), p.3191-3198

2022

Volltextzugriff (PDF)

Treatment or Psoriasis with Calcipotriene and Betamethasone Dipropionate (CAL/BDP) Cream Showed Significantly Higher Proportion of Patients with an Absolute mPASI≤2 Compared to CAL/BDP Gel/Topical Suspension in a Post-Hoc Aanalysis of Two Phase 3 Studies

Skin (Milwood, N.Y.), 2023-11, Vol.7 (6), p.s233

2023

Volltextzugriff (PDF)

A novel, fixed‐dose calcipotriol and betamethasone dipropionate cream for the topical treatment of plaque psoriasis: Direct and indirect evidence from phase 3 trials discussed at the 30th EADV Congress 2021

Journal of the European Academy of Dermatology and Venereology, 2023-01, Vol.37, p.14-19

2023

Volltextzugriff (PDF)

A novel, fixed-dose calcipotriol and betamethasone dipropionate cream for the topical treatment of plaque psoriasis: Direct and indirect evidence from phase 3 trials discussed at the 30 th EADV Congress 2021

Journal of the European Academy of Dermatology and Venereology, 2023-01, Vol.37 Suppl 1 (S1), p.14-19

2023

Volltextzugriff (PDF)

Phase 3 Trial Demonstrating High Efficacy, Favourable Safety, and Convenience of a Novel Calcipotriene and Betamethasone Dipropionate Cream

Skin (Milwood, N.Y.), 2023-03, Vol.7 (2), p.s128

2023

Volltextzugriff (PDF)

Clinical efficacy of MC2‐03 (ciclosporin eye drop) in treatment of dry eye disease patients with severe keratitis randomized in the NORTHERN LIGHTS phase 2b trial

Acta ophthalmologica (Oxford, England), 2019-12, Vol.97 (S263), p.n/a

2019

Volltextzugriff (PDF)

Identification of Akt Pathway Inhibitors Using Redistribution Screening on the FLIPR and the IN Cell 3000 Analyzer

Journal of biomolecular screening, 2005-02, Vol.10 (1), p.20-29

2005

Volltextzugriff (PDF)

A simple cell-based HTS assay system to screen for inhibitors of p53-Hdm2 protein-protein interactions

Assay and drug development technologies, 2006-12, Vol.4 (6), p.679-688

2006

Volltextzugriff (PDF)

High content translocation assays for pathway profiling

Methods in molecular biology (Clifton, N.J.), 2007, Vol.356, p.401

2007

Volltextzugriff (PDF)

Nuclear export inhibitors and kinase inhibitors identified using a MAPK-activated protein kinase 2 redistribution screen

Assay and drug development technologies, 2004-02, Vol.2 (1), p.7-20

2004

Volltextzugriff (PDF)

Pooled Analysis Demonstrating Superior Patient- Reported Psoriasis Treatment Outcomes for Calcipotriene/ Betamethasone Dipropionate Cream Versus Suspension/Gel

Journal of drugs in dermatology, 2022-03, Vol.21 (3), p.242

2022

Volltextzugriff (PDF)

Dipropionate (Bdp) Cream (Cal 0.005%/Bdp 0.064% W/W) Improves Plaque Psoriasis At Week One In A Phase 3 Trial

Skin (Milwood, N.Y.), 2022-07, Vol.6 (4), p.s42

2022

Volltextzugriff (PDF)

Calcipotriene And Betamethasone Dipropionate Cream Demonstrates High Treatment Success In Patients With Scalp Psoriasis

Skin (Milwood, N.Y.), 2022-03, Vol.6 (2), p.s9

2022

Volltextzugriff (PDF)

Identification of RAS-mitogen-activated protein kinase signaling pathway modulators in an ERF1 redistribution screen

Journal of biomolecular screening, 2006-06, Vol.11 (4), p.423-434

2006

Volltextzugriff (PDF)

Phase 3 Trial Demonstrates that MC2-01 Cream has Improved Treatment Efficacy Compared to Calcipotriene Plus Betamethasone Dipropionate Topical Suspension in Patients with Mild to Moderate Psoriasis Vulgaris

Skin (Milwood, N.Y.), 2020-09, Vol.4 (5), p.s36

2020

Volltextzugriff (PDF)

1 – 25 von 36

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(35)
Mit Volltextzugriff
(29)

Publikationsform

Artikel
(35)
Buchkapitel
(1)

Sprache

Englisch
(36)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(21)
Science & Technology
(21)
Humans
(15)
Animals
(10)
Biochemistry & Molecular Biology
(7)
Dermatology
(7)
Cricetinae
(6)
Psoriasis
(6)
Biochemical Research Methods
(5)
Cell Line
(5)
Internal Medicine
(5)
Medicine
(5)
Medicine & Public Health
(5)
Oral And Maxillofacial Surgery
(5)
Plastic Surgery
(5)
Protein Transport
(5)
Quality Of Life Research
(5)
Cell Line, Tumor
(4)
Cho Cells
(4)
Drug Evaluation, Preclinical - Methods
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Enhanced Skin Deposition of Betamethasone Dipropionate from a Novel Formulation and Drug Delivery Technology

Calcipotriene and Betamethasone Dipropionate PAD-Cream Demonstrates Greater Treatment Efficacy in Patients with Moderate-to-Severe Psoriasis Compared to Topical Suspension/Gel: A Subgroup Analysis of Two Phase 3 Studies

Sensory properties analysis of a calcipotriol and betamethasone dipropionate cream vehicle formulated with an innovative PAD Technology for the treatment of plaque psoriasis on the skin and scalp

Calcipotriol and Betamethasone Dipropionate Cream Based on PAD Technology for the Treatment of Plaque Psoriasis: A Narrative Review

Polyaphron Dispersion Technology, A Novel Topical Formulation and Delivery System Combining Drug Penetration, Local Tolerability and Convenience of Application

Profiling of multiple signal pathway activities by multiplexing antibody and GFP-based translocation assays

Validation of the Self-Reported Psoriasis Treatment Convenience Scale (PTCS)

Enhanced Skin Deposition of Betamethasone Dipropionate into the Skin of Human Volunteers from Calcipotriene/Betamethasone Dipropionate Cream Compared to Topical Suspension

A Phase 3, Randomized Trial Demonstrating the Improved Efficacy and Patient Acceptability of Fixed Dose Calcipotriene and Betamethasone Dipropionate Cream

Topical cyclosporin A as a steroid‐sparing agent for ocular rosacea

An anchored matching-adjusted indirect comparison of fixed-dose combination calcipotriol and betamethasone dipropionate (Cal/BDP) cream versus Cal/BDP foam for the treatment of psoriasis

Treatment or Psoriasis with Calcipotriene and Betamethasone Dipropionate (CAL/BDP) Cream Showed Significantly Higher Proportion of Patients with an Absolute mPASI≤2 Compared to CAL/BDP Gel/Topical Suspension in a Post-Hoc Aanalysis of Two Phase 3 Studies

A novel, fixed‐dose calcipotriol and betamethasone dipropionate cream for the topical treatment of plaque psoriasis: Direct and indirect evidence from phase 3 trials discussed at the 30th EADV Congress 2021

A novel, fixed-dose calcipotriol and betamethasone dipropionate cream for the topical treatment of plaque psoriasis: Direct and indirect evidence from phase 3 trials discussed at the 30 th EADV Congress 2021

Phase 3 Trial Demonstrating High Efficacy, Favourable Safety, and Convenience of a Novel Calcipotriene and Betamethasone Dipropionate Cream

Clinical efficacy of MC2‐03 (ciclosporin eye drop) in treatment of dry eye disease patients with severe keratitis randomized in the NORTHERN LIGHTS phase 2b trial

Identification of Akt Pathway Inhibitors Using Redistribution Screening on the FLIPR and the IN Cell 3000 Analyzer

A simple cell-based HTS assay system to screen for inhibitors of p53-Hdm2 protein-protein interactions

High content translocation assays for pathway profiling

Nuclear export inhibitors and kinase inhibitors identified using a MAPK-activated protein kinase 2 redistribution screen

Pooled Analysis Demonstrating Superior Patient- Reported Psoriasis Treatment Outcomes for Calcipotriene/ Betamethasone Dipropionate Cream Versus Suspension/Gel

Dipropionate (Bdp) Cream (Cal 0.005%/Bdp 0.064% W/W) Improves Plaque Psoriasis At Week One In A Phase 3 Trial

Calcipotriene And Betamethasone Dipropionate Cream Demonstrates High Treatment Success In Patients With Scalp Psoriasis

Identification of RAS-mitogen-activated protein kinase signaling pathway modulators in an ERF1 redistribution screen

Phase 3 Trial Demonstrates that MC2-01 Cream has Improved Treatment Efficacy Compared to Calcipotriene Plus Betamethasone Dipropionate Topical Suspension in Patients with Mild to Moderate Psoriasis Vulgaris

Suchergebnisse filtern